Asian Groups Challenge FTAs With U.S. As Anti-Generic Drugs
This article was originally published in PharmAsia News
U.S. and European Union free trade agreements with several Asian nations are coming under increasing attack by health, medical and patient groups as potential restrictions on the availability of generic drugs.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.